Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates

Expert Opinion on Investigational Drugs · Published 2026-07-30 · DOI 10.1080/13543784.2026.2710112

Authors (13)

Patricia Regina Manzine, Marina Carrasco, Thaís Antonia Alves Fernandes, Suelen Santos Alves, Laura Guzman, Leila Driouech, Mireia Millet-Sigalat, Norberto Garcia Cairasco, Jordi Olloquequi, M. Emilia Juan, Miren Ettcheto, Marcia Regina Cominetti, Antoni Camins

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Manzine, P., Carrasco, M., Fernandes, T., et al. (2026). Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2026.2710112

Related articles

• Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management · Clinical and Experimental Hypertension · 2025 · Cites or is cited by this article
• Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease · COCHRANE DATABASE OF SYSTEMATIC REVIEWS · 2026 · Cites or is cited by this article
• Advancements in longevity pharmacology research – are we finally seeing clinical progression? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Menin inhibitors for adult acute myeloid leukemia: 2025 update · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · Expert Opinion on Investigational Drugs · 2026 · Same journal